Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
24 April 2012Website:
http://www.pumabiotechnology.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 40 min agoDividend
Analysts recommendations
Institutional Ownership
PBYI Latest News
Sales of Puma Biotechnology's (PBYI) sole marketed drug, Nerlynx, have been declining in recent quarters. Stiff competition in the target market is also a woe.
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that two abstracts for its drug Alisertib to be presented at the 2024 ASCO Annual Meeting are now posted on ASCO.org.
Puma Biotechnology (PBYI) announces a smaller-than-anticipated loss in the first quarter of 2024. The company is sticking to its revenue forecast for the year.
Puma Biotechnology, Inc. (NASDAQ:PBYI) will be hosting its Q1 2024 Earnings Conference Call on May 2, 2024 at 4:30 PM ET. Present at the call will be Mariann Ohanesian, Alan Auerbach, Jeff Ludwig, and Maximo Nougues. Participants include Ed White from H.C. Wainwright and Divya Rao from TD Cowen. The operator greets everyone with a good afternoon.
Puma Biotech (PBYI) reported a quarterly loss of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.16. This is compared to earnings of $0.09 per share in the same quarter last year.
During Puma Biotechnology's (PBYI) first-quarter 2024 earnings call, investors are expected to pay close attention to the sales of its only cancer drug on the market, Nerlynx.
Puma Biotech (PBYI) ended the latest trading day at $5.49, down -0.63% from the day before.
Puma Biotechnology (PBYI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Puma Biotech (PBYI) and Repligen (RGEN). But which of these two companies is the best option for those looking for undervalued stocks?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
What type of business is Puma Biotechnology?
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
What sector is Puma Biotechnology in?
Puma Biotechnology is in the Healthcare sector
What industry is Puma Biotechnology in?
Puma Biotechnology is in the Biotechnology industry
What country is Puma Biotechnology from?
Puma Biotechnology is headquartered in United States
When did Puma Biotechnology go public?
Puma Biotechnology initial public offering (IPO) was on 24 April 2012
What is Puma Biotechnology website?
https://www.pumabiotechnology.com
Is Puma Biotechnology in the S&P 500?
No, Puma Biotechnology is not included in the S&P 500 index
Is Puma Biotechnology in the NASDAQ 100?
No, Puma Biotechnology is not included in the NASDAQ 100 index
Is Puma Biotechnology in the Dow Jones?
No, Puma Biotechnology is not included in the Dow Jones index
When does Puma Biotechnology report earnings?
The next expected earnings date for Puma Biotechnology is 02 August 2024